Ocera Therapeutics Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$117M
- Investors
-
1
Ocera Therapeutics General Information
Description
Developer of novel therapeutics designed to treat acute and chronic liver diseases. The company's novel therapeutics portfolio consists of OCR-002, an ammonia scavenger used in both intravenous (IV) and oral formulations for the treatment of hyperammonemia and STOP-HE, enabling physicians to receive biopharmaceuticals that helps in resolving neurocognitive symptoms of acute HE.
Contact Information
Website
www.ocerainc.comCorporate Office
- 555 Twin Dolphin Drive
- Suite 615
- Redwood City, CA 94065
- United States
Corporate Office
- 555 Twin Dolphin Drive
- Suite 615
- Redwood City, CA 94065
- United States
Ocera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 01-Dec-2017 | $117M | Completed | Generating Revenue | ||
| 11. Debt - General | 30-Jul-2015 | Completed | Generating Revenue | |||
| 10. 2PO | 15-Jul-2014 | Completed | Generating Revenue | |||
| 9. PIPE | 06-Nov-2013 | Completed | Generating Revenue | |||
| 8. PIPE | 16-Jul-2013 | Completed | Generating Revenue | |||
| 7. Reverse Merger | 15-Jul-2013 | Completed | Generating Revenue | |||
| 6. Debt - General | 05-Apr-2012 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 20-Feb-2008 | Completed | Startup | |||
| 4. Early Stage VC (Series B) | 10-Jul-2006 | $12M | $35.3M | Completed | Startup | |
| 3. Early Stage VC (Series A) | 17-Jan-2006 | $14.7M | $23.3M | Completed | Startup |
Ocera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 14,720,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 27.63% |
Ocera Therapeutics Comparisons
Industry
Financing
Details
Ocera Therapeutics Competitors (97)
One of Ocera Therapeutics’s 97 competitors is Cour, a Venture Capital-Backed company based in Skokie, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cour | Venture Capital-Backed | Skokie, IL | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| HepaRegenix | Venture Capital-Backed | Tubingen, Germany | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Ocera Therapeutics Patents
Ocera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021277201-A1 | Uses of ornithine phenylacetate for treating hyperammonemia | Inactive | 22-May-2020 | ||
| CA-3182891-A1 | Uses of ornithine phenylacetate for treating hyperammonemia | Pending | 22-May-2020 | ||
| EP-4153162-A1 | Uses of ornithine phenylacetate for treating hyperammonemia | Pending | 22-May-2020 | ||
| EP-4153162-A4 | Uses of ornithine phenylacetate for treating hyperammonemia | Pending | 22-May-2020 | ||
| WO-2021236522-A1 | Uses of ornithine phenylacetate for treating hyperammonemia | Inactive | 22-May-2020 | A61P1/16 |
Ocera Therapeutics Signals
Ocera Therapeutics Former Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AgeChem Financial | Venture Capital | Minority | ||
| BDC Capital | Growth/Expansion | Minority | ||
| Bonaventure Capital | Venture Capital | Minority | ||
| CDIB BioScience Venture Management | Venture Capital | Minority | ||
| Cross Creek Advisors | Venture Capital | Minority |
Ocera Therapeutics Acquisitions (1)
Ocera Therapeutics’s most recent deal was a Merger/Acquisition with Tranzyme. The deal was made on 15-Jul-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tranzyme | 15-Jul-2013 | Merger/Acquisition | Pharmaceuticals |
Ocera Therapeutics FAQs
-
When was Ocera Therapeutics founded?
Ocera Therapeutics was founded in 1998.
-
Where is Ocera Therapeutics headquartered?
Ocera Therapeutics is headquartered in Redwood City, CA.
-
What is the size of Ocera Therapeutics?
Ocera Therapeutics has 19 total employees.
-
What industry is Ocera Therapeutics in?
Ocera Therapeutics’s primary industry is Biotechnology.
-
Is Ocera Therapeutics a private or public company?
Ocera Therapeutics is a Private company.
-
What is the current valuation of Ocera Therapeutics?
The current valuation of Ocera Therapeutics is .
-
What is Ocera Therapeutics’s current revenue?
The current revenue for Ocera Therapeutics is .
-
How much funding has Ocera Therapeutics raised over time?
Ocera Therapeutics has raised $166M.
-
Who are Ocera Therapeutics’s investors?
AgeChem Financial, BDC Capital, Bonaventure Capital, CDIB BioScience Venture Management, and Cross Creek Advisors are 5 of 23 investors who have invested in Ocera Therapeutics.
-
Who are Ocera Therapeutics’s competitors?
Cour, Xalud Therapeutics, HepaRegenix, AnTolRx, and Inovio Pharmaceuticals are some of the 97 competitors of Ocera Therapeutics.
-
When was Ocera Therapeutics acquired?
Ocera Therapeutics was acquired on 01-Dec-2017.
-
Who acquired Ocera Therapeutics?
Ocera Therapeutics was acquired by Mallinckrodt Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process